Study of Diclofenac Capsules to Treat Dental Pain - Full Text View

Sponsor:	Iroko Pharmaceuticals, LLC
Information provided by:	Iroko Pharmaceuticals, LLC
ClinicalTrials.gov Identifier:	NCT00985439

Purpose

The purpose of this study is to determine whether Diclofenac Test Formulation Capsules are safe and effective for the treatment of dental pain.

Condition	Intervention	Phase
Dental Pain	Drug: Diclofenac Test (lower dose) Drug: Diclofenac Test (upper dose) Drug: Celecoxib Drug: Placebo	Phase II

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	A Phase 2, Randomized, Double-Blind, Single-Dose, Parallel-Group, Active- and Placebo-Controlled Study of Diclofenac [Test] Capsules for the Treatment of Pain After Surgical Removal of Impacted Third Molars

Resource links provided by NLM:

Drug Information available for: Diclofenac sodium Diclofenac potassium Diclofenac Celecoxib

U.S. FDA Resources

Further study details as provided by Iroko Pharmaceuticals, LLC:

Primary Outcome Measures:

Total Pain Relief (TOTPAR) [ Time Frame: 12 hours ] [ Designated as safety issue: No ]

Enrollment:	202
Study Start Date:	September 2009
Study Completion Date:	December 2009
Primary Completion Date:	December 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Diclofenac Test (lower dose)	Drug: Diclofenac Test (lower dose) Single dose
Experimental: Diclofenac Test (upper dose)	Drug: Diclofenac Test (upper dose) Single dose
Active Comparator: Celecoxib	Drug: Celecoxib Capsules 2 x 200 mg Single-dose
Placebo Comparator: Placebo	Drug: Placebo Capsules 2 Single-dose

Eligibility

Ages Eligible for Study:	18 Years to 50 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patient is male or female between 18 and 50 years of age
For women of child-bearing potential: a woman who is not pregnant and not nursing, and who is practicing an acceptable method of birth control
Patient requires extraction of 2 or more third molars
Patient must be willing to stay at the study site overnight

Exclusion Criteria:

Patient has hypersensitivity, allergy, or clinically significant intolerance to any medications to be used in the study, or related drugs
Patient has a current disease or history of a disease that will impact the study or the patient's well-being
Patient has used or intends to use any of the medications that are prohibited by the protocol
Patient has a history of drug or alcohol abuse or dependence, or patient has a positive urine drug screen or alcohol breathalyzer test
Patient has taken another investigational drug within 30 days prior to Screening

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00985439

Locations

United States, Texas
Premier Research Group Limited
Austin, Texas, United States, 78705

Sponsors and Collaborators

Iroko Pharmaceuticals, LLC

More Information

No publications provided

Responsible Party:	George Van Lear, Ph.D., Executive Director, Development, Iroko Pharmaceuticals, LLC
ClinicalTrials.gov Identifier:	NCT00985439 History of Changes
Other Study ID Numbers:	DIC2-08-03
Study First Received:	September 25, 2009
Last Updated:	June 7, 2011
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:

Toothache
Tooth Diseases
Stomatognathic Diseases
Facial Pain
Pain
Signs and Symptoms
Diclofenac
Celecoxib
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents

Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Central Nervous System Agents
Cyclooxygenase 2 Inhibitors

ClinicalTrials.gov processed this record on February 09, 2012